The Idiopathic Short Stature drugs in development market research report provides comprehensive information on the therapeutics under development for Idiopathic Short Stature, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Idiopathic Short Stature. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Idiopathic Short Stature and features dormant and discontinued products.
GlobalData tracks eight drugs in development for Idiopathic Short Stature by eight companies/universities/institutes. The top development phase for Idiopathic Short Stature is preclinical with three drugs in that stage. The Idiopathic Short Stature pipeline has eight drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Idiopathic Short Stature pipeline products market are: Lumos Pharma, Changchun GeneScience Pharmaceutical and BioMarin Pharmaceutical.
The key targets in the Idiopathic Short Stature pipeline products market include Growth Hormone Receptor, Atrial Natriuretic Peptide Receptor 2, and Growth Hormone Secretagogue Receptor Type 1.
The key mechanisms of action in the Idiopathic Short Stature pipeline product include Growth Hormone Receptor Agonist with four drugs in Phase III. The Idiopathic Short Stature pipeline products include three routes of administration with the top ROA being Subcutaneous and four key molecule types in the Idiopathic Short Stature pipeline products market including Recombinant Protein, and Small Molecule.
Idiopathic Short Stature overview
Idiopathic short stature is a condition in which the height of the individual is more than 2 standard deviations below the corresponding mean height for a given age, sex, and population, in whom no identifiable disorder is present. It can be subcategorized into familial and non-familial ISS, and according to pubertal delay.
For a complete picture of Idiopathic Short Stature’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
